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OBJECTIVES: The PROWESS study (N = 1690) demon-
strated that drotrecogin alfa (activated) signiﬁcantly
reduced 28-day mortality when added to conventional
therapy in the treatment of severe sepsis. The aim of the
current study was to generate and compare estimates of
cost-effectiveness of drotrecogin alfa (activated) in three
European counties: Germany (GM), Austria (AS) and
Switzerland (CH). METHODS: We developed a core
decision analytic model and performed cost-effectiveness
calculations from the (national) health service payer’s per-
spective. Local life-tables were applied to estimate long-
term survival beneﬁts from hospital trial mortality (ARR
= 6.1%). Trial resource use (ICU stay, duration of organ
support, hospital stay, drotrecogin alfa [activated]) was
valued using published country-speciﬁc costs. Cost-
effectiveness was expressed as the incremental cost per 
life year gained (LYG). Analysis was repeated using the
resource use patterns of European trial patients only (N
= 507); and using the resource use patterns from local
non-trial data. Analysis was repeated for patients with a
high risk of mortality (two or more organ dysfunction at
baseline, ARR = 7.3%) RESULTS: Cost effectiveness was
estimated at €14,400 (GM) and €15,400 (AS) LYG
(€22,400 and €24,700 discounting LYG at 3%) Restrict-
ing analysis to high risk patients produced better cost-
effectiveness due to greater ARR: €10,400 (GM) and
€11,300 (AS) (€13,500 and €15,100 discounting LYG at
3%). Estimates using European trial patients’ resource
use or country-speciﬁc resource use showed consistent
cost-effectiveness. The results for Switzerland are also
presented and compared. CONCLUSIONS: The cost
effectiveness of drotrecogin alfa (activated) is driven by
the drug cost and lives saved, which were assumed con-
stant for each country. The trial showed only small
increases in other resource use associated with increased
numbers of survivors. Applying local life tables, unit
costs, or patterns of care did not alter the conclusion that




LINEZOLID VERSUS TEICOPLANIN IN THE
TREATMENT OF INFECTIONS CAUSED BY
GRAM-POSITIVE BACTERIA IN SPAIN
Grau S1, Mateu-de Antonio J1,Aguado J2, Montull E3, Soto J4
1Hospital of Mar, Barcelona, Spain; 2Hospital of 12 Octubre,
Madrid, Spain; 3Pharmacia Spain, S.A, Sant Cugat del Valles,
Barcelona, Spain; 4Pharmacia Spain, S.A, Madrid, Spain
OBJECTIVES: Linezolid is a new antibiotic, active
against Gram-positive bacteria and available in intra-
venous and oral formulations with a bioavailability of
100%. The aim of this analysis is to carry out an eco-
nomic evaluation of linezolid (LZD) vs teicoplanin (TEI)
for the treatment of infections produced by Gram-
positive bacteria. METHODS: A cost-effectiveness analy-
sis was performed by building a decision analytical
model. Effectiveness data were obtained from a multi-
center randomized trial showing that LZD had signiﬁ-
cantly better efﬁcacy than TEI (95.5% vs 87.6%, p =
0.005) in treating infections caused by Gram-positive bac-
teria (ICCAC 2001; poster L-1481). Healthcare resource
utilization after the use of both antibiotics was taken from
the aforementioned clinical trial (ECCMID 2002; poster
P-486) and a local expert panel. Only direct medical costs
were included in the model (drug acquisition, length of
hospital stay, nursing time for administration of drugs,
diagnostic procedures and treatment of therapeutic fail-
ures). Drug acquisition cost data were obtained from ofﬁ-
cial sources while the rest of the data were taken from 
a national healthcare costs database. The perspective
selected for this analysis was hospital assistance and the
time horizon chosen was for 28 days, the maximum time
that patients were hospitalized in the referenced clinical
trial. RESULT: Total cost/patient was lower with LZD
versus TEI (€5,462.6 vs €5,739.8) as well as the cost/
effectiveness ratio: €5,720 vs €6,552.3 per each success-
fully cured patient. CONCLUSIONS: This pharma-
coeconomic analysis demonstrates that LZD is a more
efﬁcient therapeutic option than TEI, as it presents a
lower cost/effectiveness ratio. Moreover, as LZD pro-
duces better clinical results with less associated costs, it
is a “dominant” option over TEI and therefore LZD
could be considered as the therapeutic alternative of
choice in the treatment of infections caused by Gram-
positive bacteria in the hospital.
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OBJECTIVES: This study evaluated prescribing patterns
and associated outcomes in patients at risk for or diag-
